Global Allogenic Cell Therapies Market

Report ID : 1084 | Published : 2021-07-23 | Pages: 140 | Format:

Global Allogeneic cell therapies use the transfer of cells from a donor to a patient. Stem cells collected from the donor whose tissue type closely matches that of the patient are predominantly utilized in allogeneic cell therapies. There are various sources to get allogeneic cells, among which blood is taken from the placenta, and the umbilical cord of newborns is the prominent source of cells for allogeneic transplants. The small volume of blood comprises a high number of cells that are eligible to multiply quickly.

Moreover, raising prevalence of chronic diseases and increasing funding for stem cell research start-ups are driving the growth of allogeneic stem cell therapy market. Currently, many companies are developing a wide range of tissue-engineered products and allogeneic cell therapies aiming to bring about an era of regenerative medicine to treat people with unmet medical needs. Additionally, a rise in the prevalence of cancer and cardiovascular diseases is expected to boost the global allogeneic stem cell therapy market. For instance, JKastrup has an ongoing Phase II clinical trial for allogeneic adipose tissue-derived stromal/stem cell therapy in patients with ischemic heart disease and heart failure.

The Global Allogeneic cell therapies market is segmented on the basis of cell type, cell/tissue source, indication, and region. Based on the cell type, the market is divided into Cardiosphere-derived cells (CDCS), fibroblasts, t-cells, mesenchymal stem cells (MSCS), hematopoietic stem cells (HSCS) and others. Based on cell/tissue source, the market is segmented into skin, blood, PBC, BM and others. Based on the indication, the market is divided into acute graft-versus-host disease (gvhd), chronic ulcers and diabetic foot ulcers, osteoarthritis, crohn’s disease, cardiovascular disease, solid tumors/cancers and others (alzheimer’s disease, etc). Based on region, the maarket is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of the forecast period.

The key players of this market include Atara Biotherapeutics, Artiva Biotherapeutic, Adaptimmune Therapeutics plc, Adicet Bio, Inc., Allogene Therapeutics, Athersys, Inc., BioCardia Inc., Bluebird Bio, BlueRock Therapeutics LP, Bone Therapeutics, Celyad, Capricor Therapeutics, Cellectis, Cyto Therapeutics Pty Limited, Cynata Therapeutics, Century Therapeutics, GammaDelta Therapeutics Limited, Fate Therapeutics, Osiris Therapeutics, Inc., Organogenesis Inc., Mesoblast Ltd, MEDIPOST, Nkarta, Inc., NantKwest, Pluristem Therapeutics Inc, Regeneus, Lineage Cell Therapeutics, Inc.,  Stempeutics, Stemedica Cell Technologies, Inc., TiGenix (Takeda) and TCR² Therapeutics.

 

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Allogeneic Cell Therapies Market Snapshot

Chapter 4. Global Allogeneic Cell Therapies Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Clinical Trial/Pipeline Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape

4.8. Technology Advancement in Allogeneic Cell Therapies Market

4.9. Key Funding Activities

4.10. Impact of COVID -19 on Cell Therapy Industry

Chapter 5. Market Segmentation 1: Cell Type Estimates & Trend Analysis

5.1. Cell Type & Market Share, 2020 & 2030

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following Cell Type:

5.2.1. Cardiosphere-Derived Cells (CDCs)

5.2.2. Fibroblasts

5.2.3. T-cells

5.2.4. Mesenchymal Stem Cells (MSCs)

5.2.5. Hematopoietic Stem Cells (HSCs)

5.2.6. Others

Chapter 6. Market Segmentation 2: Cell/Tissue Source Estimates & Trend Analysis

6.1. Cell/Tissue Source & Market Share, 2020 & 2030

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following Cell/Tissue Source:

6.2.1. Skin

6.2.2. Blood

6.2.3. PBC

6.2.4. BM

6.2.5. Others

Chapter 7. Market Segmentation 3: Indication type Estimates & Trend Analysis

7.1. Indication Type & Market Share, 2020 & 2030

7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2030 for the following Indication Type:

7.2.1. Acute graft-versus-host disease (GVHD)

7.2.2. Chronic Ulcers and Diabetic Foot Ulcers

7.2.3. Osteoarthritis

7.2.4. Crohn's Disease

7.2.5. Cardiovascular Disease

7.2.6. Solid Tumors/Cancers

7.2.7. Others (Alzheimer's Disease, etc.)

Chapter 8. Allogeneic Cell Therapies Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Allogeneic Cell Therapies Market revenue (US$ Million) estimates and forecasts by Cell Type, 2020-2030

8.1.2. North America Allogeneic Cell Therapies Market revenue (US$ Million) estimates and forecasts by Cell/Tissue Source, 2020-2030

8.1.3. North America Allogeneic Cell Therapies Market revenue (US$ Million) estimates and forecasts by Indication, 2020-2030

8.1.4. North America Allogeneic Cell Therapies Market revenue (US$ Million) estimates and forecasts by Country, 2020-2030

8.1.4.1. U.S.

8.1.4.2. Canada

8.2. Europe

8.2.1. Europe Allogeneic Cell Therapies Market revenue (US$ Million) by Cell Type, 2020-2030

8.2.2. Europe Allogeneic Cell Therapies Market revenue (US$ Million) by Cell/Tissue Source, 2020-2030

8.2.3. Europe Allogeneic Cell Therapies Market revenue (US$ Million) by Indication, 2020-2030

8.2.4. Europe Allogeneic Cell Therapies Market revenue (US$ Million) by Country, 2020-2030

8.2.4.1. Germany

8.2.4.2. Poland

8.2.4.3. France

8.2.4.4. Italy

8.2.4.5. Spain

8.2.4.6. UK

8.2.4.7. Rest of Europe

8.3. Asia Pacific

8.3.1. Asia Pacific Allogeneic Cell Therapies Market revenue (US$ Million) by Cell Type, 2020-2030

8.3.2. Asia Pacific Allogeneic Cell Therapies Market revenue (US$ Million) by Cell/Tissue Source, 2020-2030

8.3.3. Asia Pacific Allogeneic Cell Therapies Market revenue (US$ Million) by Indication, 2020-2030

8.3.4. Asia Pacific Allogeneic Cell Therapies Market revenue (US$ Million) by Country, 2020-2030

8.3.4.1. China

8.3.4.2. India

8.3.4.3. Japan

8.3.4.4. Australia

8.3.4.5. Rest of Asia Pacific

8.4. Latin America

8.4.1. Latin America Allogeneic Cell Therapies Market revenue (US$ Million) by Cell Type, 2020-2030

8.4.2. Latin America Allogeneic Cell Therapies Market revenue (US$ Million) by Cell/Tissue Source, 2020-2030

8.4.3. Latin America Allogeneic Cell Therapies Market revenue (US$ Million) by Indication, 2020-2030

8.4.4. Latin America Allogeneic Cell Therapies Market revenue (US$ Million) by country, 2020-2030

8.4.4.1. Brazil

8.4.4.2. Rest of Latin America

8.5. MEA

8.5.1. MEA Allogeneic Cell Therapies Market revenue (US$ Million) by Cell Type, (US$ Million) 2020-2030

8.5.2. MEA Allogeneic Cell Therapies Market revenue (US$ Million) by Cell/Tissue Source, 2020-2030

8.5.3. MEA Allogeneic Cell Therapies Market revenue (US$ Million) by Indication, 2020-2030

8.5.4. MEA Allogeneic Cell Therapies Market revenue (US$ Million) by country, 2020-2030

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Atara Biotherapeutics

9.2.2. Artiva Biotherapeutic

9.2.3. Adaptimmune Therapeutics plc

9.2.4. Adicet Bio, Inc.

9.2.5. Allogene Therapeutics

9.2.6. Athersys, Inc.

9.2.7. BioCardia Inc.

9.2.8. Bluebird Bio

9.2.9. BlueRock Therapeutics LP

9.2.10. Bone Therapeutics

9.2.11. Celyad

9.2.12. Capricor Therapeutics

9.2.13. Cellectis

9.2.14. Cyto Therapeutics Pty Limited

9.2.15. Cynata Therapeutics

9.2.16. Century Therapeutics

9.2.17. GammaDelta Therapeutics Limited

9.2.18. Fate Therapeutics

9.2.19. Osiris Therapeutics, Inc.

9.2.20. Organogenesis Inc.

9.2.21. Mesoblast Ltd

9.2.22. MEDIPOST

9.2.23. Nkarta, Inc.

9.2.24. NantKwest

9.2.25. Pluristem Therapeutics Inc.

9.2.26. Regeneus

9.2.27. Lineage Cell Therapeutics, Inc.

9.2.28. Stempeutics

9.2.29. Stemedica Cell Technologies, Inc.

9.2.30. TiGenix (Takeda) 

9.2.31. TCR² Therapeutics

9.2.32. Talaris Therapeutics, Inc.

9.2.33. Other Prominent Players

Global Allogeneic Cell Therapies Market Segmentation:

Global Allogeneic Cell Therapies Market Revenue (US$ Mn) by Cell Type

  • Cardiosphere-Derived Cells (CDCs)
  • Fibroblasts
  • T-cells
  • Mesenchymal Stem Cells (MSCs)
  • Hematopoietic Stem Cells (HSCs)
  • Others

Global Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Tissue Source

  • Skin
  • Blood
  • PBC
  • BM
  • Others

Global Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Indication

  • Acute graft-versus-host disease (GVHD)
  • Chronic Ulcers and Diabetic Foot Ulcers
  • Osteoarthritis
  • Crohn’s Disease
  • Cardiovascular Disease
  • Solid Tumors/Cancers
  • Others (Alzheimer’s Disease, etc.)

Global Allogeneic Cell Therapies Market Revenue (US$ Mn) Based on Region

Europe Allogeneic Cell Therapies Market Revenue (US$ Mn) by Country

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America Allogeneic Cell Therapies Market Revenue (US$ Mn) by Country

  • U.S.
  • Canada

Asia Pacific Allogeneic Cell Therapies Market Revenue (US$ Mn) by Country

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America Allogeneic Cell Therapies Market Revenue (US$ Mn) by Country

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa Allogeneic Cell Therapies Market Revenue (US$ Mn) by Country

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

 

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients